

Hikma appoints Julie Hill, as Senior Vice President, Corporate Quality Compliance/Health and Safety

London 1 February 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that Julie Hill has been appointed Senior Vice President, Corporate Quality Compliance/Health and Safety, effective immediately.

Julie will report to Hikma's CEO, Riad Mishlawi, and she will also join the company's senior management as a member of Hikma's Executive Committee.

"Julie's appointment to this role is a great recognition of her outstanding leadership qualities, valuable insights, and her ability to contribute significantly to Hikma's continued growth and success," said Riad Mishlawi, Hikma's CEO.

Julie joined Hikma through the 2016 acquisition of Roxane Laboratories and most recently served as Vice President, Quality, for Hikma's Generics business. Under Julie's leadership, Hikma's Generics team and Columbus facility have had the distinction of achieving many successful quality inspections from the US Food and Drug Administration and the regulatory bodies of multiple other nations.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760 / +44 7776 477050
uk-investors@hikma.uk.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com